Company Insight – Page 27 – media

EU green light for Roche’s Tecentriq

Roche has received European Commission(EC) approval for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab) to treat specific lung and bladder cancers. The green light means that it can be used as monotherapy for people in the EU with previously-treated locally advanced or metastatic non-small cell cancer (NSCLC), or those with metastatic urothelial carcinoma (mUC) who have received a platinum-based chemotherapy or who are ineligible to receive cisplatin chemotherapy.
- Source: Pharmatimes
- 566
- September 26, 2017
bladder cancer Company Insight immunotherapy lung
MIT’s new injection tech delivers multiple vaccines with one poke

Regardless of what it’s protecting you against, few people would likely say that getting a vaccine injection is an altogether enjoyable vaccine. Fortunately, engineers at the Massachusetts Institute of Technology are coming to the rescue with a new 3D fabrication technique that could allow for multiple doses of a drug or vaccine to be delivered to a patient over an extended period of time — with just one jab needed.
- Source: digitaltrends
- 734
- September 25, 2017
Company Insight fabrication needle-phobic vaccine
Remote Diagnostic introduces new system for monitoring and defibrillation

UK-based firm Remote Diagnostic Technologies (RDT) has introduced a new system, Tempus ALS, to enable monitoring and defibrillation to improve emergency responses.
- Source: medicaldevice-network
- 518
- September 22, 2017
Company Insight defibrillation Tempus ALS
Medtronic secures FDA approval for Intellis spinal cord stimulator

Medtronic has secured the US Food and Drug Administration (FDA) approval for its next generation spinal cord stimulator branded as Intellis platform for the management of certain forms of chronic intractable pain.
- Source: medicaldevices-business-review
- 1,005
- September 21, 2017
chronic Company Insight spinal cord stimulator
K2M launches Everest minimally invasive XTower instrumentation

K2M Group Holdings has launched Everest minimally invasive (MI) XTower instrumentation, an enhancement to the Everest MI XT spinal system, at the Society for Minimally Invasive Spine Surgery Annual Forum (SMISS) event.
- Source: orthopedicdevices.medicaldevices-business-review
- 838
- September 19, 2017
Company Insight invasive MI surgical
Medtronic launches new surgical navigation system for ENT procedures

Medtronic has launched a new surgical navigation system named as StealthStation ENT to help surgeons in treating conditions within the ear, nose, and throat (ENT) anatomy.
- Source: medicaldevices-business-review
- 733
- September 15, 2017
Company Insight ENT surgical
Apple is testing whether the Apple Watch can detect heart problems

Apple is working with partners to test whether its smartwatch can be used to detect common heart conditions, an effort that would make its device a "must have" for millions of people worldwide. The company is partnering up with a group of clinicians at Stanford, as well as telemedicine vendor American Well, to test whether Apple Watch's heart rate sensor can detect abnormal heart rhythms in a cohort of patients, according to two people familiar. The people requested anonymity as these plans have not yet been made public.
- Source: finance.yahoo
- 834
- September 14, 2017
abnormal heart rhythm Arrhythmias Company Insight
Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has entered into a definitive agreement under which CooperSurgical will acquire PARAGARD® (intrauterine copper contraceptive), a product within its global Women’s Health business, in a $1.1 billion cash transaction. PARAGARD® had revenues of approximately $168 million for the trailing twelve month period ending June 30, 2017. This transaction includes Teva’s manufacturing facility in Buffalo, NY, which produces PARAGARD® exclusively.
- Source: finance.yahoo
- 535
- September 13, 2017
Company Insight Market Views oncology PARAGARD
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for 8:30 AM EDT this morning; dial-in and webcast details are provided below.
- Source: Globenewswire
- 3,273
- September 11, 2017
cancer Company Insight T-cell
Sanofi wins tentative FDA nod for Admelog insulin lispro injection

Sanofi announced that the U.S. Food and Drug Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Source: yahoo
- 741
- September 7, 2017
Company Insight diabetes FDA insulin New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.